|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
US5681835A
(en)
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
|
US5510357A
(en)
|
1995-02-28 |
1996-04-23 |
Eli Lilly And Company |
Benzothiophene compounds as anti-estrogenic agents
|
|
EP0833828B1
(en)
|
1995-06-09 |
2002-11-20 |
Novartis AG |
Rapamycin derivatives
|
|
NZ333903A
(en)
|
1996-07-24 |
2000-02-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal
|
|
US5916916A
(en)
|
1996-10-10 |
1999-06-29 |
Eli Lilly And Company |
1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
|
|
ZA982877B
(en)
|
1997-04-09 |
1999-10-04 |
Lilly Co Eli |
Treatment of central nervous system disorders with selective estrogen receptor modulators.
|
|
CA2287387C
(en)
|
1997-05-14 |
2010-02-16 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for destruction of selected proteins
|
|
JP2001517664A
(ja)
|
1997-09-23 |
2001-10-09 |
イーライ・リリー・アンド・カンパニー |
ベンゾチオフェン類
|
|
ES2220005T3
(es)
|
1998-06-16 |
2004-12-01 |
Pfizer Products Inc. |
Combinaciones terapeuticas que comprenden un modulador selectivo del receptor de estrogeno y prostaglandina e2.
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
US6333344B1
(en)
|
1999-05-05 |
2001-12-25 |
Merck & Co. |
Prolines as antimicrobial agents
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7041298B2
(en)
|
2000-09-08 |
2006-05-09 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
CA2432932A1
(en)
|
2001-02-16 |
2002-08-29 |
Mark A. Scialdone |
Angiogenesis-inhibitory tripeptides, compositions and their methods of use
|
|
HN2002000136A
(es)
|
2001-06-11 |
2003-07-31 |
Basf Ag |
Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
|
|
US7030141B2
(en)
|
2001-11-29 |
2006-04-18 |
Christopher Franklin Bigge |
Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
|
|
ES2251677T3
(es)
|
2002-01-22 |
2006-05-01 |
Warner-Lambert Company Llc |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
|
|
WO2004005248A1
(en)
|
2002-07-02 |
2004-01-15 |
Novartis Ag |
Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
|
|
US7915293B2
(en)
|
2003-05-30 |
2011-03-29 |
Rigel Pharmaceuticals, Inc. |
Ubiquitin ligase inhibitors
|
|
ATE412650T1
(de)
|
2003-07-11 |
2008-11-15 |
Warner Lambert Co |
Isethionat salz eines selektiven cdk4 inhibitors
|
|
US7932382B2
(en)
|
2004-01-16 |
2011-04-26 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
|
WO2005094818A1
(en)
|
2004-03-23 |
2005-10-13 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of iap
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
BRPI0511350A
(pt)
|
2004-07-02 |
2007-12-04 |
Genentech Inc |
composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
|
|
MX2007007195A
(es)
|
2004-12-20 |
2007-10-08 |
Genentech Inc |
Inhibidores de pirrolidina de iap.
|
|
TW200639163A
(en)
|
2005-02-04 |
2006-11-16 |
Genentech Inc |
RAF inhibitor compounds and methods
|
|
ES2456671T3
(es)
|
2005-02-25 |
2014-04-23 |
Tetralogic Pharmaceuticals Corporation |
Inhibidores diméricos de IAP
|
|
CN100383139C
(zh)
|
2005-04-07 |
2008-04-23 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
|
|
WO2006113942A2
(en)
|
2005-04-20 |
2006-10-26 |
Schering Corporation |
Method of inhibiting cathepsin activity
|
|
KR20080042158A
(ko)
|
2005-08-31 |
2008-05-14 |
셀진 코포레이션 |
이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
|
|
BRPI0708524A2
(pt)
|
2006-03-03 |
2011-05-31 |
Novartis Ag |
compostos de n-formil hidroxilamina
|
|
WO2007101347A1
(en)
|
2006-03-07 |
2007-09-13 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
US20070218138A1
(en)
*
|
2006-03-20 |
2007-09-20 |
Bittorf Kevin J |
Pharmaceutical Compositions
|
|
JP5286646B2
(ja)
|
2006-04-19 |
2013-09-11 |
トヨタ自動車株式会社 |
スルホン基含有モノマーの重合方法
|
|
JP5230610B2
(ja)
|
2006-05-05 |
2013-07-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
二価ｓｍａｃ模倣物およびその使用
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
諾華公司 |
吡咯并嘧啶化合物及其用途
|
|
JP2009544620A
(ja)
|
2006-07-20 |
2009-12-17 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
自己免疫疾患及び炎症のためのプロリン尿素ｃｃｒ１アンタゴニスト
|
|
US20100056495A1
(en)
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
RU2448101C2
(ru)
|
2006-08-30 |
2012-04-20 |
Селджин Корпорейшн |
5-замещенные изоиндолиновые соединения
|
|
MX2009001989A
(es)
|
2006-08-30 |
2009-03-09 |
Celgene Corp |
Compuestos de isoindolina 5-substituidos.
|
|
BRPI0716880A2
(pt)
|
2006-09-08 |
2013-10-15 |
Pfizer Prod Inc |
Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
|
|
KR20080035180A
(ko)
|
2006-10-18 |
2008-04-23 |
삼성전자주식회사 |
화상형성장치, 화상형성시스템 및 그 제어방법
|
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
|
WO2008109057A1
(en)
|
2007-03-02 |
2008-09-12 |
Dana-Farber Cancer Institute, Inc. |
Organic compounds and their uses
|
|
JP5454943B2
(ja)
|
2007-04-12 |
2014-03-26 |
ジョイアント ファーマスーティカルズ、インク． |
抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
|
|
WO2008128171A2
(en)
|
2007-04-13 |
2008-10-23 |
The Regents Of The University Of Michigan |
Diazo bicyclic smac mimetics and the uses thereof
|
|
PE20130150A1
(es)
|
2007-04-30 |
2013-02-27 |
Genentech Inc |
Inhibidores de las iap
|
|
WO2008144925A1
(en)
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
JP5451602B2
(ja)
|
2007-06-08 |
2014-03-26 |
アッヴィ・インコーポレイテッド |
キナーゼ阻害薬としての５−ヘテロアリール置換インダゾール類
|
|
US8648069B2
(en)
|
2007-06-08 |
2014-02-11 |
Abbvie Inc. |
5-substituted indazoles as kinase inhibitors
|
|
KR20100038108A
(ko)
|
2007-07-25 |
2010-04-12 |
브리스톨-마이어스 스큅 컴퍼니 |
트리아진 키나제 억제제
|
|
ES2534899T3
(es)
|
2007-08-06 |
2015-04-30 |
Janssen Pharmaceutica, N.V. |
Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
|
|
PL2201012T3
(pl)
|
2007-10-11 |
2014-11-28 |
Astrazeneca Ab |
Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
|
|
EP2058312A1
(en)
|
2007-11-09 |
2009-05-13 |
Universita' degli Studi di Milano |
SMAC mimetic compounds as apoptosis inducers
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
|
PE20110547A1
(es)
|
2008-10-29 |
2011-08-04 |
Celgene Corp |
Compuestos de isoindolina con actividad anticancerigena
|
|
JP5487214B2
(ja)
|
2008-12-19 |
2014-05-07 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
|
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
|
US8063102B2
(en)
|
2009-03-13 |
2011-11-22 |
N.V. Organon |
Tetrahydronaphthalen-2-ol derivatives
|
|
US20120135089A1
(en)
|
2009-03-17 |
2012-05-31 |
Stockwell Brent R |
E3 ligase inhibitors
|
|
NZ595708A
(en)
|
2009-05-26 |
2014-03-28 |
Abbvie Bahamas Ltd |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
WO2010141805A1
(en)
|
2009-06-05 |
2010-12-09 |
Janssen Pharmaceutica Nv |
Heterocyclic amides as modulators of trpa1
|
|
JP2012532929A
(ja)
|
2009-07-13 |
2012-12-20 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
二機能性のステープリングされたポリペプチドおよびそれらの使用
|
|
EP2784076A1
(en)
|
2009-10-28 |
2014-10-01 |
Joyant Pharmaceuticals, Inc. |
Dimeric SMAC mimetics
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
EP2536706B1
(en)
|
2010-02-11 |
2017-06-14 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
SG186389A1
(en)
|
2010-06-30 |
2013-01-30 |
Univ Brandeis |
Small-molecule-targeted protein degradation
|
|
EP2619184B1
(en)
|
2010-09-24 |
2018-05-23 |
The Regents of the University of Michigan |
Deubiquitinase inhibitors and methods for use of the same
|
|
AR083797A1
(es)
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
|
CN102477017A
(zh)
|
2010-11-23 |
2012-05-30 |
苏州波锐生物医药科技有限公司 |
四氢萘衍生物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
|
|
CN102477033A
(zh)
|
2010-11-23 |
2012-05-30 |
苏州波锐生物医药科技有限公司 |
苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
|
|
AU2011338615B2
(en)
|
2010-12-07 |
2017-07-27 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
|
US20140243282A1
(en)
|
2010-12-31 |
2014-08-28 |
Satish Reddy Kallam |
Methods and compositions for designing novel conjugate therapeutics
|
|
US8889684B2
(en)
|
2011-02-02 |
2014-11-18 |
Boehringer Ingelheim International Gmbh |
Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
|
|
CA2834535A1
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
MX352672B
(es)
|
2011-09-27 |
2017-12-04 |
Amgen Inc |
Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
|
|
WO2013071039A1
(en)
|
2011-11-09 |
2013-05-16 |
Ensemble Therapeutics |
Macrocyclic compounds for inhibition of inhibitors of apoptosis
|
|
WO2013071035A1
(en)
|
2011-11-09 |
2013-05-16 |
Ensemble Therapeutics |
Macrocyclic compounds for inhibition of inhibitors of apoptosis
|
|
CN103159736B
(zh)
|
2011-12-10 |
2015-05-13 |
通化济达医药有限公司 |
取代的吡唑激酶抑制剂
|
|
US9273046B2
(en)
|
2011-12-31 |
2016-03-01 |
Beigene, Ltd. |
Fused tricyclic compounds as Raf kinase inhibitors
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
US20150119435A1
(en)
|
2012-05-11 |
2015-04-30 |
Yale University |
Compounds useful for promoting protein degradation and methods using same
|
|
EP2855483B1
(en)
|
2012-05-24 |
2017-10-25 |
Novartis AG |
Pyrrolopyrrolidinone compounds
|
|
NZ631477A
(en)
|
2012-05-30 |
2016-12-23 |
Hoffmann La Roche |
Substituted pyrrolidine-2-carboxamides
|
|
US9345740B2
(en)
|
2012-07-10 |
2016-05-24 |
Bristol-Myers Squibb Company |
IAP antagonists
|
|
US9371568B2
(en)
|
2012-07-31 |
2016-06-21 |
Novartis Ag |
Markers associated with human double minute 2 inhibitors
|
|
WO2014025759A1
(en)
|
2012-08-09 |
2014-02-13 |
Bristol-Myers Squibb Company |
Iap antagonists
|
|
DK2882737T3
(da)
|
2012-08-09 |
2019-05-13 |
Celgene Corp |
Fast form af (s)-3-(4-((4-morpholinmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorid
|
|
TWI586668B
(zh)
|
2012-09-06 |
2017-06-11 |
第一三共股份有限公司 |
二螺吡咯啶衍生物之結晶
|
|
WO2014047024A1
(en)
|
2012-09-18 |
2014-03-27 |
Bristol-Myers Squibb Company |
Iap antagonists
|
|
US9603889B2
(en)
|
2012-10-02 |
2017-03-28 |
Bristol-Myers Squibb Company |
IAP antagonists
|
|
TW201428002A
(zh)
|
2012-11-09 |
2014-07-16 |
必治妥美雅史谷比公司 |
用於抑制細胞凋亡抑制劑之巨環化合物
|
|
US9637493B2
(en)
|
2012-12-20 |
2017-05-02 |
Merck Sharp & Dohme Corp. |
Substituted pyrrolopyrimidines as HDM2 inhibitors
|
|
TW201429969A
(zh)
|
2012-12-20 |
2014-08-01 |
Merck Sharp & Dohme |
作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
NL2011274C2
(en)
|
2013-08-06 |
2015-02-09 |
Illumicare Ip B V 51 |
Groundbreaking platform technology for specific binding to necrotic cells.
|
|
SI2958916T1
(sl)
|
2013-02-21 |
2018-11-30 |
Pfizer Inc. |
Trdne oblike selektivnih zaviralcev CDK4/6
|
|
CA2902856C
(en)
|
2013-02-28 |
2021-02-16 |
Amgen Inc. |
A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
|
|
AU2014236812B2
(en)
|
2013-03-14 |
2018-03-01 |
Amgen Inc. |
Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP3019517A1
(en)
|
2013-07-12 |
2016-05-18 |
Bristol-Myers Squibb Company |
Iap antagonists
|
|
ES2883289T3
(es)
|
2013-12-20 |
2021-12-07 |
Astex Therapeutics Ltd |
Compuestos heterocíclicos bicíclicos y sus usos en terapia
|
|
JP2017507964A
(ja)
|
2014-03-13 |
2017-03-23 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
エストロゲン受容体モジュレーターを用いた治療的組合せ
|
|
WO2015152433A1
(en)
|
2014-03-31 |
2015-10-08 |
Hanmi Pharm. Co., Ltd. |
Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
AU2015247817C1
(en)
|
2014-04-14 |
2022-02-10 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
CN107406424B
(zh)
|
2014-12-18 |
2020-08-25 |
豪夫迈·罗氏有限公司 |
雌激素受体调节剂及其用途
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
|
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
US10730870B2
(en)
|
2015-03-18 |
2020-08-04 |
Arvinas Operations, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
HUE061213T2
(hu)
|
2015-04-16 |
2023-05-28 |
Novartis Ag |
Ribociklib tabletta
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP4212536B1
(en)
|
2015-07-02 |
2025-02-19 |
F. Hoffmann-La Roche AG |
Benzoxazepin oxazolidinone compounds and methods of use
|
|
WO2017011371A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
CA2988436A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
AU2016349781A1
(en)
|
2015-11-02 |
2018-05-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
|
CN107028931A
(zh)
|
2016-02-04 |
2017-08-11 |
上海宣泰医药科技有限公司 |
一种紫杉醇药物组合物及其药物制剂、制备方法和用途
|
|
KR20180119570A
(ko)
*
|
2016-03-15 |
2018-11-02 |
메리맥 파마슈티컬즈, 인크. |
항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
|
|
US11395820B2
(en)
|
2016-03-16 |
2022-07-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Small molecules against cereblon to enhance effector t cell function
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
AU2017246452C1
(en)
|
2016-04-06 |
2021-06-03 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
|
EP3445357B1
(en)
|
2016-04-22 |
2021-05-26 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of egfr and methods of use
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
BR112018075206A2
(pt)
|
2016-06-06 |
2019-03-19 |
Celgene Corporation |
tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018071606A1
(en)
|
2016-10-11 |
2018-04-19 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
IL290809B2
(en)
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
CA3042301A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
|
|
KR102674902B1
(ko)
|
2016-12-01 |
2024-06-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
|
TWI770093B
(zh)
|
2016-12-15 |
2022-07-11 |
瑞士商赫孚孟拉羅股份公司 |
製備苯并氧氮呯(benzoxazepin)噁唑啶酮化合物之方法
|
|
MX2019007646A
(es)
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
AU2018211975B2
(en)
|
2017-01-26 |
2022-05-26 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
BR112019015484A2
(pt)
*
|
2017-01-31 |
2020-04-28 |
Arvinas Operations Inc |
ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
|
|
MX394540B
(es)
|
2017-04-28 |
2025-03-21 |
Hoffmann La Roche |
Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
CA3095912A1
(en)
*
|
2018-04-13 |
2019-10-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
MD3784664T2
(ro)
|
2018-04-26 |
2025-06-30 |
Pfizer |
Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline
|
|
CN113164779A
(zh)
|
2018-12-06 |
2021-07-23 |
雷迪厄斯制药公司 |
治疗cdk4/6抑制剂耐药性癌症的方法
|
|
CN113196734B
(zh)
|
2018-12-12 |
2023-12-15 |
瑞典爱立信有限公司 |
用于处理订户的通信服务的方法和功能
|
|
IL320609A
(en)
|
2019-08-26 |
2025-07-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
US10836749B1
(en)
|
2019-09-23 |
2020-11-17 |
Accutar Biotechnology Inc. |
Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
|
|
FI3835298T3
(fi)
|
2019-12-12 |
2024-07-29 |
Accutar Biotechnology Inc |
Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja
|
|
AR123492A1
(es)
|
2020-09-14 |
2022-12-07 |
Arvinas Operations Inc |
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
|
|
SI4214202T1
(sl)
|
2020-09-15 |
2025-05-30 |
Pfizer Inc. |
Trdne oblike inhibitorja cdk4
|
|
CN116744925A
(zh)
|
2020-12-14 |
2023-09-12 |
阿尔维纳斯运营股份有限公司 |
用四氢萘衍生物作为雌激素受体降解剂治疗乳腺癌的方法
|
|
EP4377296A1
(en)
|
2021-07-26 |
2024-06-05 |
Arvinas Operations, Inc. |
Methods of manufacturing a bifunctional compound
|
|
CN113816927B
(zh)
|
2021-11-23 |
2022-02-25 |
苏州国匡医药科技有限公司 |
一种arv-471中间体的制备方法
|
|
EP4440623A4
(en)
|
2021-11-30 |
2025-12-10 |
Institute For Cancer Res D/B/A The Res Institute Of Fox Chase Cancer Center |
Polytherapy for the treatment of cancer
|
|
CN114085213B
(zh)
|
2022-01-20 |
2022-03-25 |
苏州国匡医药科技有限公司 |
一种arv-471的制备方法
|
|
CN117045800A
(zh)
|
2022-05-06 |
2023-11-14 |
上海科技大学 |
mTOR抑制剂增强靶向蛋白降解药物功效的应用
|
|
WO2024049926A1
(en)
|
2022-08-31 |
2024-03-07 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
|
WO2024083716A1
(en)
|
2022-10-17 |
2024-04-25 |
Astrazeneca Ab |
Combinations of a serd for the treatment of cancer
|
|
WO2024167904A1
(en)
|
2023-02-07 |
2024-08-15 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor
|